GlaxoSmithKline’s chief executive Emma Walmsley recently announced that the drugmaker is looking at Pfizer’s consumer products business. But Walmsley stated that while it is considering the acquisition, GSK would not overpay for the asset.
Walmsley, who was formerly the head of GSK's consumer healthcare division, said that the company’s pharmaceuticals business and pharma research and development is still its top priority. Still, Walmsley believes that GSK's consumer business has room to grow and that the British drugmaker has traditionally been competent in integrating large acquisitions.
Read the Reuters report